Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
BACKGROUND
Several cellular pathways are implicated in the pathogenesis of pulmonary arterial hypertension (PAH) and attempts to arrest disease progression with a single drug would not be expected to succeed in the medium term. In clinical practice, combination therapy is often used in patients deteriorating on monotherapy, despite the absence of firm evidence from randomized controlled controls.


METHODS
From January 2005 to August 2009, 112 patients with World Health Organisation Functional Class (FC) II-IV PAH deteriorating on monotherapy received non-parenteral combination therapy at six Australian PAH expert hospitals. Combination therapy included bosentan, sitaxentan, ambrisentan, iloprost and sildenafil. Data were prospectively collected for survival status, 6-min walk distance, FC and echocardiographic parameters at the start of monotherapy through to commencement of combination therapy and at 6-monthly intervals thereafter.


RESULTS
After varying periods of monotherapy (18.7±13.4onths), survival estimates on combination therapy were 88%, 71% and 61% for the additional 1, 2 and 3years respectively. Survival on dual therapy in patients with idiopathic PAH/familial PAH was 93% at 1year and 79% at 2years, and for scleroderma-related PAH, 72% at 1 year and 48% at year 2 after initiation of combination therapy. In survivors, dual therapy reversed the deterioration in FC, from 3.1±0.6 on monotherapy to 2.2±0.6 at 12months. Similarly, dual therapy improved 6-min walk distance from 316±119m to 406±129m at 12months, and sequential echocardiography demonstrated a fall in pulmonary artery systolic pressure and improved right ventricular function.


CONCLUSIONS
Dual non-parenteral therapy appears safe and effective and should be considered for PAH patients who are deteriorating on monotherapy to improve long-term outcomes.
St Vincent’s Hospital, Xavier 4, Victoria St, Darlinghurst, NSW 2010, Australia. amkeogh@stvincents.com.au
A
A
Keogh
G
G
Strange
E
E
Kotlyar
T
T
Williams
D
D
Kilpatrick
P
P
Macdonald
K
K
Brown
A
A
Pidoux
F
F
Kermeen
P
P
Steele
B
B
Dalton
E
E
Gabbay
D000328:Adult; D000368:Aged; D001315:Australia / Q000453:epidemiology; D000077300:Bosentan; D003299:Cooperative Behavior; D004359:Drug Therapy, Combination; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D011446:Prospective Studies; D011687:Purines / Q000008:administration & dosage; D011724:Pyridazines / Q000008:administration & dosage; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage; D013450:Sulfones / Q000008:administration & dosage; D015996:Survival Rate / Q000639:trends; D055815:Young Adult
D010666:Phenylpropionates; D010879:Piperazines; D011687:Purines; D011724:Pyridazines; D013449:Sulfonamides; D013450:Sulfones; D000068677:Sildenafil Citrate; C467894:ambrisentan; D000077300:Bosentan